Cognitive performance during the first year of treatment in first-episode schizophrenia: A case-control study

Psychological Medicine

Volumn 45, Issue 13, 2015, Pages 2873-2883

  Olivier, M R ^a   Killian, S ^a   Chiliza, B ^a   Asmal, L ^a   Schoeman, R ^a   Oosthuizen, P P ^a   Kidd, M ^b   Emsley, R ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Flupenthixol decanoate; neurocognition; outcome; psychosis

Indexed keywords

FLUPENTIXOL; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ATTENTION; CASE CONTROL STUDY; COGNITION; COMPLICATION; FACTORIAL ANALYSIS; FEMALE; HUMAN; LEARNING; LONGITUDINAL STUDY; MALE; PHYSIOLOGY; PROBLEM SOLVING; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; SHORT TERM MEMORY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; CASE-CONTROL STUDIES; COGNITION; FACTOR ANALYSIS, STATISTICAL; FEMALE; FLUPENTHIXOL; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY, SHORT-TERM; PROBLEM SOLVING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING; YOUNG ADULT;

EID: 84941259017     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715000860     Document Type: Article

References (46)

1. Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM (2014). A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Frontiers in Psychiatry 4, 182
2. Addington D, Addington J (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry 22 (Suppl.), 39-44
3. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association: Washington, DC
4. Barder HE, Sundet K, Rund BR, Evensen J, Haahr U, Ten Velden HW, Joa I, Johannessen JO, Langeveld H, Larsen TK, Melle I, Opjordsmoen S, Rossberg JI, Simonsen E, Vaglum P, McGlashan T, Friis S (2013). Neurocognitive development in first episode psychosis 5 years follow-up: associations between illness severity and cognitive course. Schizophrenia Research 149, 63-69
5. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E,Willson DF, Alvir JM,Woerner MG, Geisler S, Kane JM, Lieberman JA (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry 157, 549-559
6. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M (1994). A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica 89, 62-67
7. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD (2008). Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biological Psychiatry 63, 505-511
8. Bozikas VP, Andreou C (2011). Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Australian and New Zealand Journal of Psychiatry 45, 93-108
9. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2011). The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophrenia Bulletin 37, 1209-1217
10. Cannon-Spoor HE, Potkin SG, Wyatt RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470-484
11. Chen EY, Hui CL, Dunn EL, Miao MY, Yeung WS, Wong CK, Chan WF, Tang WN (2005). A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Research 77, 99-104
12. Cohen J (1988). Statistical Power Analysis for the Behavioural Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ
13. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 166, 675-682
14. De Wit H (2010). Flupenthixol. In Encyclopedia of Psychopharmacology: Springer Reference (ed. I. Stolerman and L. Rice), pp. 538-539 Springer-Verlag: Berlin Heidelberg
15. Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, Maison P (2014). Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. European Journal of Clinical Pharmacology 70, 127-134
16. Dickinson D, Ragland JD, Gold JM, Gur RC (2008). General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biological Psychiatry 64, 823-827
17. EkerholmM, FirusWS, Fagerberg T, Soderman E, Terenius L, Agartz I, Jonsson EG, Nyman H (2012). Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. Psychiatry Research 200, 144-152
18. Emsley R, Rabinowitz J, Torreman M (2003). The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia Research 61, 47-57
19. First MB, Spitzer RLGM, Williams LBW (1994). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). New York State Psychiatric Institute, Biometrics Research: New York
20. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG (2007). Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archive of General Psychiatry 64, 1115-1122
21. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (2010). Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35, 1053-1062
22. Harvey PD, Rabinowitz J, Eerdekens M, DavidsonM(2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry 162, 1888-1895
23. International Conference on Harmonization (1996). ICH Harmonized Tripartite Guidelines for Good Clinical Practice. Brookwood Medical Publications Ltd: Richmond, Surrey
24. Kahn RS, Keefe RS (2013). Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 70, 1107-1112
25. Kay SR, Fizbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin 13, 261-267
26. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007a). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 64, 633-647
27. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophrenia Bulletin 39, 417-435
28. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 161, 985-995
29. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2006). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry 59, 97-105
30. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 25, 201-222
31. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA (2007b). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164, 1061-1071
32. Lieberman JA,PerkinsDO, JarskogLF (2007).Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectrums 12, 1-13
33. Mishara AL, Goldberg TE (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry 55, 1013-1022
34. Nielsen RE (2011). Cognition in schizophrenia-A systematic review. Drug Discovery Today: Therapeutic Strategies 8, 43-48
35. Nuechterlein KH, Green MF (2006). MATRICS Consensus Battery Manual. MATRICS Assessment Inc.: Los Angeles
36. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, FentonWS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E,Weinberger DR, Young AS, Zalcman S,Marder SR (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry 165, 203-213
37. Nuechterlein KH, Subotnik KL, Green MF, Ventura J, Asarnow RF, Gitlin MJ, Yee CM, Gretchen-Doorly D, Mintz J (2011). Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophrenia Bulletin 37 (Suppl. 2), S33-S40
38. Porter RJ, Bowie CR, Jordan J, Malhi GS (2013). Cognitive remediation as a treatment for major depression: a rationale, review of evidence and recommendations for future research. Australian and New Zealand Journal of Psychiatry 47, 1165-1175
39. Rajji TK, Voineskos AN, Butters MA, Miranda D, Arenovich T, Menon M, Ismail Z, Kern RS, Mulsant BH (2013). Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery. American Journal of Geriatric Psychiatry 21, 108-118
40. Shen X, Xia J, Adams CE (2012). Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD009777. DOI: 10.1002/14651858. CD009777.pub2
41. Stern R, White T (2003). Neuropsychological Assessment Battery: Mazes. Psychological Assessment Resources, Incorporated: Lutz, FL
42. Stip E, Chouinard S, Boulay LJ (2005). On the trail of a cognitive enhancer for the treatment of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 219-232
43. Tandon R, Nasrallah HA, Keshavan MS (2009). Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophrenia Research 110, 1-23
44. Woodberry KA, McFarlane WR, Giuliano AJ, Verdi MB, Cook WL, Faraone SV, Seidman LJ (2013). Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophrenia Research 146, 87-94
45. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007). A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophrenia Research 89, 211-224
46. World Health Organization (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychological Medicine 28, 551-558